Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Neochem Bio
Quarter-by-quarter operating performance
Financials of Neochem Bio
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 49 | 48 | 61 | 84 | 111 |
| Expenses + | 45 | 44 | 55 | 71 | 91 |
| Operating Profit | 4 | 4 | 6 | 13 | 20 |
| OPM % | 7% | 9% | 10% | 15% | 18% |
| Other Income + | 0 | 1 | 1 | 2 | 2 |
| Interest | 1 | 2 | 3 | 4 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 2 | 3 | 10 | 17 |
| Tax % | 25% | 28% | 31% | 25% | 30% |
| Net Profit + | 1 | 1 | 2 | 7 | 12 |
| EPS in Rs | 3.23 | 2.10 | 2.89 | 11.15 | 7.03 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Neochem Bio
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 7 | 7 | 17 |
| Reserves | 1 | 3 | 6 | 13 | 62 |
| Borrowings + | 23 | 26 | 33 | 36 | 18 |
| Other Liabilities + | 19 | 16 | 18 | 23 | 20 |
| Total Liabilities | 46 | 51 | 63 | 78 | 117 |
| Fixed Assets + | 12 | 15 | 19 | 19 | 20 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 6 |
| Other Assets + | 34 | 36 | 45 | 60 | 91 |
| Total Assets | 46 | 51 | 63 | 78 | 117 |
Financials of Neochem Bio
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | -1 | -1 | -1 | 2 | -19 |
| Cash from Investing Activity + | -3 | -3 | 12 | 2 | -7 |
| Cash from Financing Activity + | 4 | 4 | -11 | -4 | 26 |
| Net Cash Flow | 0 | -0 | 0 | -0 | 0 |
| Free Cash Flow | -4 | -4 | 11 | 4 | -22 |
| CFO/OP | -36% | -23% | -10% | 17% | -81% |
Financials of Neochem Bio
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 102 | 107 | 100 | 108 | 161 |
| Inventory Days | 141 | 173 | 172 | 157 | 143 |
| Days Payable | 186 | 155 | 142 | 117 | 56 |
| Cash Conversion Cycle | 58 | 125 | 131 | 148 | 247 |
| Working Capital Days | 17 | 19 | 30 | 38 | 164 |
| ROCE % | 12% | 14% | 27% | 28% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…